欢迎访问《岭南现代临床外科》官方网站,今天是

岭南现代临床外科 ›› 2022, Vol. 22 ›› Issue (05): 451-457.DOI: 10.3969/j.issn.1009-976X.2022.05.004

• 论著与临床研究 • 上一篇    下一篇

乳腺癌辅助化疗后预防性使用乙二醇化重组人粒细胞刺激因子的成本效果分析和对生活质量的影响

陈玩娜1#, 梁小立1#, 张展强1#, 徐荷洋2, 林勃1, 张兆禧1, 禹菊1, 郑亮1, 黄津耀1, 张景1, 陆漪琳1, 黄佳泳1, 李瑞霞1, 李杰3,*, 吕伟明1,*   

  1. 1.中山大学附属第一医院甲状腺外科,广州 510080;
    2.中国医学科学院肿瘤医院深圳医院,深圳 518116;
    3.广州市妇女儿童医疗中心甲乳外科,广州 510623
  • 通讯作者: *吕伟明,Email: lvwm@mail.sysu.edu.cn;李杰,Email:lijie78@mail.sysu.edu.cn
  • 作者简介:#陈玩娜、梁小立、张展强为共同第一作者
  • 基金资助:
    广东省科技厅工业高新领域项目(2017A010105029); 广东省医学科研基金(A2020569)

Cost-effectiveness and Qol of PEGrhGCSF prophylaxis for breast cancer patients receiving adjuvant chemotherapy

CHEN Wan-na1#, LIANG Xiao-li1#, ZHANG Zhan-qiang1#, XU He-yang2, LIN Bo1, ZHANG Zhao-xi1, YU Ju1, ZHENG Liang1, HUANG Jin-yao1, ZHANG Jing1, LU Yi-lin1, HUANG Jia-yong1, LI Rui-xia1, LI Jie3,*, LV Wei-ming1,*   

  1. 1. Department of Thyroid Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China;
    2. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China;
    3. Department of Breast and Thyroid Surgery, Guangzhou Women and Children′s Medical Center, Guangzhou 510623, China.
  • Received:2022-09-15 Online:2022-10-20 Published:2022-12-06
  • Contact: LV Wei-ming, lvwm@mail.sysu.edu.cn; LI Jie, lijie78@mail.sysu.edu.cn
  • About author:#CHEN Wan-na, LIANG Xiao-li and ZHANG Zhan-qiang contributed equal to this article

摘要: 目的 探究乳腺癌辅助化疗后预防性使用聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)的成本效果及对生活质量的影响。方法 本研究是一项前瞻性队列研究。纳入我科乳腺癌辅助化疗的患者,根据是否预防性使用PEG-rhG-CSF分组,并进行血常规监测。比较两组化疗间期重度粒细胞减少发生率、延迟化疗率、成本费用指标及生活质量,计算增量成本效果比(Incremental cost benefit ratio,ICER)。结果 共256例患者纳入分析。与对照组相比,PEG-rhG-CSF组重度中性粒细胞减少和延迟化疗的发生率较低,生理状况方面生活质量更好,总费用稍高,针对重度粒细胞减少发生率和延迟化疗率的ICER分别为25.32元/1%和24.45元/1%。结论 乳腺癌辅助化疗后预防性使用PEG-rhG-CSF效果良好并提高生活质量,性价比较高。

关键词: 乳腺癌, 化疗, PEG-rhG-CSF, 成本效果分析, 生活质量

Abstract: Objective To analyze the cost-effectiveness of PEGrhGCSF prophylaxis for breast cancer patients receiving adjuvant chemotherapy and its effect on quality of life (Qol). Methods This is a prospective cohort study. The breast cancer patients receiving adjuvant chemotherapy in our department were included and grouped by whether PEGrhGCSF was used or not. Complete blood count was monitored during chemotherapy cycle. Medical related bills were recorded and Qol was evaluated using FACT-B questionnaire. The rates of severe neutropenia and delay of next chemotherapy, medical related cost and Qol were compared between groups. Incremental cost benefit ratio (ICER) was calculated. Results Totally 256 patients were included in analysis. Compared with control group, PEG-rhG-CSF group had lower rates of severe neutropenia (9.3% vs. 20.6%, P = 0.030) and delay of next chemotherapy (5.2% vs. 15.9%, P=0.010), and better Qol in physical well-being scale. The total cost was higher in PEG-rhG-CSF group, but the difference was not statistically significant (2102.95 CNY vs. 1816.85 CNY, P=0.31). The ICERs for severe neutropenia and delay of next chemotherapy were 25.32 CNY/1% and 24.45 CNY/1%, respectively. Conclusion PEGrhGCSF prophylaxis for breast cancer patients receiving adjuvant chemotherapy was cost-effective and associated with better Qol.

Key words: breast cancer, chemotherapy, PEG-rhG-CSF, cost-effective analysis, quality of life

中图分类号: